277 related articles for article (PubMed ID: 33962341)
1. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations.
Shaji D; Yamamoto S; Saito R; Suzuki R; Nakamura S; Kurita N
Biophys Chem; 2021 Aug; 275():106608. PubMed ID: 33962341
[TBL] [Abstract][Full Text] [Related]
2. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
3. Docking Paradigm in Drug Design.
Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV
Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135
[TBL] [Abstract][Full Text] [Related]
4. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
5. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2.
Yassine R; Makrem M; Farhat F
Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and Computational Approach of Selected Phytocompounds from
Rakib A; Paul A; Chy MNU; Sami SA; Baral SK; Majumder M; Tareq AM; Amin MN; Shahriar A; Uddin MZ; Dutta M; Tallei TE; Emran TB; Simal-Gandara J
Molecules; 2020 Aug; 25(17):. PubMed ID: 32872217
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
8. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
9. A computational evaluation of targeted oxidation strategy (TOS) for potential inhibition of SARS-CoV-2 by disulfiram and analogues.
Xu L; Tong J; Wu Y; Zhao S; Lin BL
Biophys Chem; 2021 Sep; 276():106610. PubMed ID: 34089978
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
11. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
12. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
13. In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease.
Deshmukh N; Talkal R; Lakshmi B
J Biomol Struct Dyn; 2024 Jun; 42(9):4395-4411. PubMed ID: 37325819
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.
Sardanelli AM; Isgrò C; Palese LL
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807773
[TBL] [Abstract][Full Text] [Related]
16. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
[No Abstract] [Full Text] [Related]
17. Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus
Abouelela ME; Assaf HK; Abdelhamid RA; Elkhyat ES; Sayed AM; Oszako T; Belbahri L; El Zowalaty AE; Abdelkader MSA
Molecules; 2021 Mar; 26(6):. PubMed ID: 33801151
[TBL] [Abstract][Full Text] [Related]
18. Potential SARS-CoV-2 protease M
Kouznetsova VL; Huang DZ; Tsigelny IF
Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
[TBL] [Abstract][Full Text] [Related]
19. Insight into crystal structures and identification of potential styrylthieno[2,3-
El Bakri Y; Ahmad B; Saravanan K; Ahmad I; Bakhite EA; Younis O; Al-Waleedy SAH; Ibrahim OF; Nafady A; Mague JT; Mohamed SK
J Biomol Struct Dyn; 2024 May; 42(8):4325-4343. PubMed ID: 37318002
[TBL] [Abstract][Full Text] [Related]
20. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
